Immunovant, Inc. Quarterly Debt-to-equity in % from Q3 2019 to Q3 2024

Taxonomy & unit
ratio: %
Description
Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary
Immunovant, Inc. quarterly Debt-to-equity history and growth rate from Q3 2019 to Q3 2024.
  • Immunovant, Inc. Debt-to-equity for the quarter ending September 30, 2024 was 8.4 %, a 36.8% decline year-over-year.
Debt-to-equity, Quarterly (%)
Debt-to-equity, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date
Q3 2024 8.4 -4.89 -36.8% Sep 30, 2024
Q2 2024 7.93 -3.52 -30.7% Jun 30, 2024
Q1 2024 9.32 +0.66 +7.62% Mar 31, 2024
Q4 2023 10.5 +2.22 +26.9% Dec 31, 2023
Q3 2023 13.3 +5.63 +73.6% Sep 30, 2023
Q2 2023 11.5 +4.46 +63.8% Jun 30, 2023
Q1 2023 8.67 +1.39 +19.1% Mar 31, 2023
Q4 2022 8.26 +2.04 +32.8% Dec 31, 2022
Q3 2022 7.65 +2.22 +40.9% Sep 30, 2022
Q2 2022 7 +2.16 +44.6% Jun 30, 2022
Q1 2022 7.28 +2.13 +41.3% Mar 31, 2022
Q4 2021 6.22 +0.27 +4.54% Dec 31, 2021
Q3 2021 5.43 -2.03 -27.2% Sep 30, 2021
Q2 2021 4.84 -7.81 -61.8% Jun 30, 2021
Q1 2021 5.15 -17.5 -77.2% Mar 31, 2021
Q4 2020 5.95 -29.5 -83.2% Dec 31, 2020
Q3 2020 7.46 +83.9 Sep 30, 2020
Q2 2020 12.6 Jun 30, 2020
Q1 2020 22.6 Mar 31, 2020
Q4 2019 35.5 Dec 31, 2019
Q3 2019 -76.4 Sep 30, 2019
* An asterisk sign (*) next to the value indicates that the value is likely invalid.